| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $1,231,784 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Barry Richard | President & CEO | 5 | $1.17M | 0 | $0 | $1.17M |
| Cook Robert Christopher | Chief Operating & Legal Office | 1 | $39,940 | 0 | $0 | $39,940 |
| Anderson Robert Eugene Jr | director | 1 | $24,940 | 0 | $0 | $24,940 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Over the last 12 months, insiders at Cassava Sciences, Inc. have bought $1.23M and sold $0 worth of Cassava Sciences, Inc. stock.
On average, over the past 5 years, insiders at Cassava Sciences, Inc. have bought $2.47M and sold $253,948 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Barry Richard (President & CEO) — $1.17M. Cook Robert Christopher (Chief Operating & Legal Office) — $39,940. Anderson Robert Eugene Jr (director) — $24,940.
The last purchase of 8,600 shares for transaction amount of $24,940 was made by Anderson Robert Eugene Jr (director) on 2025‑11‑24.
| 2025-11-24 | Anderson Robert Eugene Jr | director | 8,600 0.018% | $2.90 | $24,940 | -25.86% | ||
| 2025-11-20 | Barry Richard | President & CEO | 150,000 0.3259% | $2.76 | $414,000 | -18.06% | ||
| 2025-11-19 | Barry Richard | President & CEO | 73,385 0.1519% | $2.75 | $201,809 | -21.45% | ||
| 2025-09-30 | Cook Robert Christopher | Chief Operating & Legal Office | 13,725 0.0284% | $2.91 | $39,940 | -5.50% | ||
| 2025-09-22 | Barry Richard | President & CEO | 7,172 0.0146% | $2.28 | $16,352 | +20.26% | ||
| 2025-09-19 | Barry Richard | President & CEO | 47,308 0.0983% | $2.29 | $108,319 | +22.15% | ||
| 2025-09-18 | Barry Richard | President & CEO | 190,633 0.3855% | $2.24 | $426,424 | +21.40% | ||
| 2024-11-29 | Sale | Schoen Eric | Chief Financial Officer | 61,800 0.1291% | $3.86 | $238,468 | -39.06% | |
| 2024-11-29 | Sale | Kupiec James William | Chief Medical Officer | 4,000 0.0084% | $3.87 | $15,480 | -39.06% | |
| 2023-08-23 | ROBERTSON SANFORD | director | 30,000 0.0716% | $17.45 | $523,500 | +22.09% | ||
| 2023-08-22 | Barry Richard | director | 16,571 0.0382% | $16.65 | $275,907 | +23.58% | ||
| 2023-08-21 | Barry Richard | director | 1,906 0.0046% | $16.80 | $32,021 | +26.67% | ||
| 2023-03-07 | Barry Richard | director | 77,276 0.1893% | $25.76 | $1.99M | -10.00% | ||
| 2023-03-06 | Barry Richard | director | 11,565 0.0275% | $26.13 | $302,193 | -13.83% | ||
| 2022-08-23 | Barry Richard | 36,159 0.0849% | $23.79 | $860,223 | +3.87% | |||
| 2022-08-23 | Kupiec James William | Chief Clinical Dev. Officer | 2,500 0.006% | $24.44 | $61,100 | +3.87% | ||
| 2022-08-12 | ROBERTSON SANFORD | 100,000 0.253% | $20.69 | $2.07M | +28.77% | |||
| 2022-08-12 | Schoen Eric | Chief Financial Officer | 2,500 0.0061% | $19.95 | $49,875 | +28.77% | ||
| 2020-09-24 | BARBIER REMI | President and CEO | 10,000 0.0395% | $9.59 | $95,900 | +368.35% | ||
| 2020-09-18 | ROBERTSON SANFORD | director | 36,281 0.1287% | $8.92 | $323,627 | +340.97% |
| Barry Richard | President & CEO | 938060 1.9418% | $1.99M | 10 | 0 | +6.06% |
| Cook Robert Christopher | Chief Operating & Legal Office | 13725 0.0284% | $29,097.00 | 1 | 0 | |
| Anderson Robert Eugene Jr | director | 8600 0.0178% | $18,232.00 | 1 | 0 | |
| BLACK BEAR OFFSHORE MASTER FUND LP | 10 percent owner | 5810453 12.028% | $12.32M | 71 | 9 | +9.41% |
| Sabretooth Master Fund, L.P. | 10 percent owner | 4263076 8.8248% | $9.04M | 0 | 3 | |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | 10 percent owner | 3230204 6.6867% | $6.85M | 10 | 17 | <0.0001% |
| BARBIER REMI | President and CEO | 1078855 2.2333% | $2.29M | 6 | 112 | +182.46% |
| ROBERTSON SANFORD | director | 886851 1.8358% | $1.88M | 14 | 0 | +100.84% |
| FRIEDMANN NADAV | Chief Operating Officer | 259255 0.5367% | $549,620.60 | 12 | 16 | +17.71% |
| SCHOENHARD GRANT | Chief Scientific Officer | 48157 0.0997% | $102,092.84 | 1 | 8 | +3.06% |
| RODDY PETER S | CFO | 42396 0.0878% | $89,879.52 | 28 | 17 | +4.96% |
| O DONNELL MICHAEL J | director | 5775 0.012% | $12,243.00 | 0 | 2 | |
| Schoen Eric | Chief Financial Officer | 0 0% | $0 | 4 | 1 | +278.74% |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 0 0% | $0 | 0 | 4 | |
| Kupiec James William | Chief Medical Officer | 0 0% | $0 | 1 | 1 | +3.87% |
$5,413,611 | 159 | 6.12% | $99.47M | |
Cassava Sciences, Inc. (SAVA) | $30,470,407 | 140 | 20.39% | $102.41M |
$9,405,928 | 107 | 12.61% | $119.71M | |
$155,630,608 | 79 | -24.53% | $100.73M | |
$17,525,882 | 60 | 5.22% | $104.6M | |
$8,075,370 | 52 | 3.29% | $112.91M | |
$4,898,715 | 46 | 40.75% | $92.71M | |
$77,146,704 | 43 | 13.28% | $95.58M | |
$140,595,157 | 34 | 17.93% | $107.13M | |
$33,128,160 | 18 | -13.64% | $84.48M | |
$156,530,514 | 13 | 45.71% | $115.5M | |
$17,741,707 | 13 | 30.23% | $93.4M | |
$1,073,250 | 10 | 19.46% | $106.46M | |
$9,999,920 | 10 | -40.03% | $115.83M | |
$280,338 | 8 | 34.18% | $112.69M | |
$106,599,960 | 6 | -7.63% | $86.73M | |
$68,692,148 | 6 | -39.10% | $101.82M | |
$112,382,168 | 4 | -48.89% | $105.96M | |
$193,889 | 4 | 73.66% | $88.15M |
| Increased Positions | 46 | +35.11% | 3M | +21.99% |
| Decreased Positions | 49 | -37.4% | 3M | -21.97% |
| New Positions | 22 | New | 2M | New |
| Sold Out Positions | 17 | Sold Out | 1M | Sold Out |
| Total Postitions | 128 | -2.29% | 14M | +0.02% |
| Vanguard Group Inc | $4,785.00 | 4.77% | 2.29M | +119,451 | +5.5% | 2025-09-30 |
| Marshall Wace, Llp | $4,308.00 | 4.29% | 2.06M | +2M | +2,774.32% | 2025-09-30 |
| Blackrock, Inc. | $2,945.00 | 2.94% | 1.41M | -136,751 | -8.85% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,010.00 | 2% | 961,500 | -22,100 | -2.25% | 2025-09-30 |
| Jpmorgan Chase & Co | $1,182.00 | 1.18% | 565,439 | -191,622 | -25.31% | 2025-09-30 |
| Two Sigma Investments, Lp | $1,181.00 | 1.18% | 564,998 | +38,483 | +7.31% | 2025-09-30 |
| Geode Capital Management, Llc | $1,124.00 | 1.12% | 537,901 | +15,022 | +2.87% | 2025-09-30 |
| Goldman Sachs Group Inc | $988.00 | 0.99% | 472,860 | -140,283 | -22.88% | 2025-09-30 |
| Gmt Capital Corp | $941.00 | 0.94% | 450,100 | 0 | 0% | 2025-09-30 |
| 683 Capital Management, Llc | $888.00 | 0.89% | 425,000 | +425,000 | New | 2025-09-30 |